Back to results
US 2023/0053437 A1Published application
Lipid compounds and lipid nanoparticle compositions
AssigneeSuzhou Abogen Biosciences Co., Ltd.
InventorBo Ying
Life of this patent
Estimating the term…
Abstract
Provided herein are lipid compounds that can be used in combination with other lipid components, such as neutral lipids, cholesterol and polymer conjugated lipids, to form lipid nanoparticles for delivery of therapeutic agents (e.g., nucleic acid molecules) for therapeutic or prophylactic purposes, including vaccination. Also provided herein are lipid nanoparticle compositions comprising said lipid compounds.
Claims65
A compound of Formula (I):
- or a pharmaceutically acceptable salt, prodrug or stereoisomer thereof, wherein:
- G1 and G2 are each independently a bond, C2-C12 alkylene, or C2-C12 alkenylene;
- L1 is —OC(═O)R1, —C(═O)OR′, —OC(═O)OR′, —C(═O)R1, —OR′, —S(O)xR1, —S—SR1, —C(═O)SR1, —SC(═O)R1, —NRaC(═O)R1, —C(═O)NRbRc, —NRaC(═O)NRbRc, —OC(═O)NRbRc, —NRaC(═O)OR1, —SC(═S)R1, —C(═S)SR′, —C(═S)R1, —CH(OH)R1, —P(═O)(ORb)(ORc), —(C6-C10 arylene)-R1, -(6- to 10-membered heteroarylene)-R1, or R1;
- L2 is —OC(═O)R2, —C(═O)OR2, —OC(═O)OR2, —C(═O)R2, —OR2, —S(O)xR2, —S—SR2, —C(═O)SR2, —SC(═O)R2, —NRdC(═O)R2, —C(═O)NReRf, —NRdC(═O)NReRf, —OC(═O)NReRf, —NRdC(═O)OR2, —SC(═S)R2, —C(═S)SR2, —C(═S)R2, —CH(OH)R2, —P(═O)(ORe)(ORf), —(C6-C10 arylene)-R2, -(6- to 10-membered heteroarylene)-R2, or R2;
- R1 and R2 are each independently C6-C24 alkyl or C6-C24 alkenyl;
- Ra, Rb, Rd, and Re are each independently H, C1-C12 alkyl, or C2-C12 alkenyl;
- Rc and Rf are each independently C1-C12 alkyl or C2-C12 alkenyl;
- G3 and G4 are each independently C1-C12 alkylene;
- L3 and L4 are each independently —OC(═O)—, —C(═O)O—, —OC(═O)O—, —C(═O)—, —O—, —S(O)x—, —S—S—, —C(═O)S—, —SC(═O)—, —NRaC(═O)—, —C(═O)NRb—, —NRaC(═O)NRO—, —OC(═O)NRb—, —NRaC(═O)O—, —SC(═S)—, —C(═S)S—, —C(═S)—, —CH(OH)—, —P(═O)(ORb)O—, —(C6-C10 arylene)-, or -(6- to 10-membered heteroarylene)-;
- G5 is C2-C24 alkylene, C2-C24 alkenylene, C3-C8 cycloalkylene, or C3-C8 cycloalkenylene;
- R3 is —N(R4)R5 or —OR6;
- R4 is hydrogen, C1-C12 alkyl, C3-C8 cycloalkyl, C3-C8 cycloalkenyl, or C6-C10 aryl;
- R5 is C1-C12 alkyl;
- or R4 and R5 together with the nitrogen to which they are attached form a cyclic moiety;
- R6 is hydrogen, C1-C12 alkyl, C3-C8 cycloalkyl, C3-C8 cycloalkenyl, or C6-C10 aryl;
- x is 0, 1, or 2;
- n is 1, 2, or 3;
- m is 1, 2, or 3;
- and
- wherein each alkyl, alkenyl, cycloalkyl, cycloalkenyl, aryl, alkylene, alkenylene, cycloalkylene, cycloalkenylene, arylene, heteroarylene, and cyclic moiety is independently optionally substituted.
17 more elements
A compound in Table 1, or a pharmaceutically acceptable salt, prodrug or stereoisomer thereof.
Dependencies are inferred from the claim text.